ReviewJournal of multidisciplinary healthcare2025
Comprehensive Clinical Analysis of Rilonacept in the Treatment of Cryopyrin-Associated Periodic Syndromes: A Systematic Review.
Review in Journal of multidisciplinary healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting IL-1β: a potential strategy for alleviating the immunopathology of aortic aneurysms.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cryopyrin-associated periodic syndromes (CAPS), a group of interleukin-1 (IL-1) mediated autoinflammatory disorders, were incorporated into China's "Second List of Rare Diseases" in 2023. Notably, rilonacept, an IL-1 inhibitor approved in the United States since 2008, has been a key treatment for CAPS. However, comprehensive analysis of its efficacy and safety are limited. This systematic review aims to assess rilonacept for CAPS treatment and provide evidence-based therapeutic recommendations. Methods: We used medical subject headings terms and free-text keywords related to rilonacept and CAPS to perform a systematic literature search. This search covered databases including PubMed, Ovid/Embase, The Cochrane Library, and Chinese databases (CNKI, Wanfang, and VIP) from their inception to September 30, 2024. A multidimensional systematic review was then conducted, collating the efficacy, safety, cost-effectiveness, innovativeness, suitability, and accessibility of rilonacept in treating CAPS. Results: Out of 1223 screened publications, three clinical studies including two sequential randomized controlled trials were selected based on the established criteria. Notably, no economic evaluations were identified. Treatment with rilonacept resulted in a reduction of approximately two points in key symptom scores for patients, with significant improvements in all outcome measures such as the number of flare days and high-sensitivity C-reactive protein levels. Adverse reactions were mostly mild to moderate, and with favorable long-term tolerability. Rilonacept meets current clinical needs due to its ease of use, demonstrating strong innovativeness and suitability. Its cost-effectiveness and accessibility warrant further examination post-market entry, yet it exhibits considerable potential for widespread use. Conclusion: Rilonacept demonstrates significant effectiveness in treating CAPS with a favorable overall safety profile. It shows high innovativeness and acceptable suitability, with the potential for improved cost-effectiveness and accessibility. We anticipate that the effective treatment of CAPS with rilonacept will encourage further clinical and fundamental research, offering valuable insights for the treatment of other autoinflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.